Relief Therapeutics Hldg Ag Stock Price, News & Analysis

Relief Therapeutics (OTCQB: RLFTF) announced a positive safety update regarding aviptadil from its U.S. partner, NRx Pharmaceuticals, as part of the NIH-sponsored ACTIV-3b study. The Independent Data Safety Monitoring Board analyzed over 300 patients and found no new safety concerns, recommending continued enrollment to reach 640 patients. Relief's lead drug, RLF-100(TM), aims to treat respiratory deficiency due to COVID-19. The company also broadened its portfolio through recent acquisitions and collaborations.

Relief Therapeutics Holding SA has announced positive interim results from a clinical trial of its nasal spray Sentinox for SARS-CoV-2 infected patients. Conducted by APR Applied Pharma Research, the study confirmed Sentinox's safety and tolerability, suggesting it may effectively reduce viral load in nasal mucosa. Out of 30 patients, all treated with Sentinox tested negative for the virus by Day 21, while 10% of the control group remained positive. The study aims to confirm these promising results across a larger cohort.

Relief Therapeutics announced the publication of two studies in the Journal of Wound Care, showcasing the effectiveness of its Nexodyn(R) Acid-Oxidizing Solution (AOS) for treating hard-to-heal ulcers. The studies included 60 patients treated with Nexodyn(R) AOS alongside standard care, resulting in 68.3% of wounds healing or improving by day 70 and significant reductions in wound size. A follow-up study indicated that 35.5% of patients experienced complete healing by week 32. The findings support Nexodyn's safety and effectiveness, highlighting its potential as a valuable treatment option.

Relief Therapeutics has reported positive trial results for its drug aviptadil in treating critical COVID-19 patients with respiratory failure. In a study published in the Journal of Infectious Diseases and Treatment, aviptadil demonstrated a 60-day survival rate of 81%, significantly higher than the 21% survival rate of standard care (P<.0001). Additionally, the treatment showed a 9-fold advantage in recovery from respiratory failure (P<.0001). These results further support Relief's ongoing clinical programs and partnerships aimed at addressing high unmet medical needs.

Relief Therapeutics announced that its U.S. partner, NRx Pharmaceuticals, has submitted a revised Investigational New Drug module for ZYESAMI (aviptadil) to the FDA, confirming Nephron Pharmaceuticals can supply the drug commercially. Additionally, NRx received positive audit results from a European QP Auditor at a separate facility. Relief's lead candidate, RLF-100 (aviptadil), targets respiratory deficiency due to COVID-19 and has undergone late-stage clinical testing.

Relief Therapeutics reported positive safety findings for ZYESAMI (RLF-100) in the NIH-sponsored ACTIV-3b study. The Independent Data Safety Monitoring Board reviewed data from 231 patients and confirmed no new safety concerns, recommending continued patient enrollment. The company emphasizes its commitment to addressing unmet medical needs with innovative therapies while also strengthening its pipeline through collaborations and acquisitions. The progress of RLF-100, particularly in treating respiratory issues related to COVID-19, remains a focus for Relief.

Relief Therapeutics announces that its subsidiary, APR Applied Pharma Research, published findings in the Journal of Wound Care indicating that Nexodyn(R) Acid-Oxidizing Solution (AOS) exhibits superior wound healing compared to standard care. Conducted by experts in Austria, the study involved 50 patients and demonstrated significant improvements including a healing rate of 32% with Nexodyn(R) versus 8% with standard treatment. The study confirmed Nexodyn(R)'s safety, tolerability, and its ability to reduce wound pH, promoting faster healing.

Relief Therapeutics Holding SA (OTCQB: RLFTF) announced that its U.S. partner, NRx Pharmaceuticals, has reported positive top-line data for ZYESAMI™ (RLF-100™/aviptadil) in highly comorbid COVID-19 patients. The treatment showed a threefold increase in one-year survival rates, consistent with prior phase 2b/3 trial results indicating enhanced 60-day survival rates. Relief focuses on clinical-stage therapies, with RLF-100™ targeting respiratory deficiencies due to COVID-19. The company also diversifies its pipeline through collaborations and recent acquisitions.

Relief Therapeutics Holding SA reported its half-year results for 2021, highlighting a focus on developing therapeutic products for severe diseases. The company has transformed into a multi-product, revenue-generating entity, primarily driven by the acquisition of APR Applied Pharma Research. Key developments include the filing of an NDA for ACER-001 and ongoing trials for RLF-100 (aviptadil), aimed at treating COVID-19 and other serious conditions. Despite a net loss of CHF 14.7 million, Relief maintains a strong cash position of CHF 40 million, positioning itself for strategic growth.